XML 26 R14.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Earnings (Loss) Per Share | 9 Months Ended
--- | ---
Sep. 30, 2022
Earnings Per Share [Abstract] |
Earnings (Loss) Per Share | Earnings (Loss) Per Share Basic earnings (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted-average number of common shares outstanding during the period. Basic and diluted earnings per share ("EPS") for the Predecessor was calculated in accordance with the two-class method. Predecessor net loss attributable to Legacy Valaris used in our computations of basic and diluted EPS was adjusted to exclude net income allocated to non-vested shares granted to our employees and non-employee directors. Weighted-average shares outstanding used in our computation of diluted EPS is calculated using the treasury stock method and for the Successor includes the effect of all potentially dilutive stock equivalents, including warrants, restricted stock unit awards and performance stock unit awards and for the Predecessor included the effect of all potentially dilutive stock options and excluded non-vested shares. The following table is a reconciliation of the weighted-average shares used in our basic and diluted EPS computations for the three and nine months ended September 30, 2022 (Successor), three and five months ended September 30, 2021 (Successor) and four months ended April 30, 2021 (Predecessor) (in millions):
| Three Months Ended September 30, |  |  |
| 2022 |  | 2021 |  |  |
Income (loss) from continuing operations attributable to our shares | $ | 74.3 |  |  | $ | (54.5) |  |  |  |
Weighted average shares outstanding: |  |  |  |  |  |
Basic | 75.1 |  |  | 75.0 |  |  |  |
Effect of stock equivalents | 0.5 |  |  | — |  |  |  |
Diluted | 75.6 |  |  | 75.0 |  |  |  |
| Successor |  |  | Predecessor (1)
| Nine Months Ended September 30, 2022 |  | Five Months Ended September 30, 2021 |  |  | Four Month Ended April 30, 2021
Income (loss) from continuing operations attributable to our shares | $ | 147.3 |  |  | $ | (60.7) |  |  |  | $ | (4,467.0) |
Weighted average shares outstanding: |  |  |  |  |  |
Basic | 75.0 |  |  | 75.0 |  |  |  | 199.6 |
Effect of stock equivalents | 0.5 |  |  | — |  |  |  | — |
Diluted | 75.5 |  |  | 75.0 |  |  |  | 199.6 |
(1)No amounts were allocated to non-vested share awards in these periods given that losses are not allocated to non-vested share awards. Anti-dilutive share awards totaling 38,000 and 103,000 were excluded from the computation of diluted EPS for the three and nine months ended September 30, 2022 (Successor), respectively. Due to the net loss position of the Successor during the three and five months ended September 30, 2021, our potentially dilutive instruments were not included in the computation of diluted EPS as the effect of including these shares in the calculation would have been anti-dilutive. For the Successor, during the three and five months ended September 30, 2021, there were approximately 600,000 and 400,000 anti-dilutive shares, respectively. Due to the net loss position of the Predecessor, during the four months ended April 30, 2021, our potentially dilutive instruments were not included in the computation of diluted EPS as the effect of including these shares in the calculation would have been anti-dilutive. For the Predecessor, during the four months ended April 30, 2021, anti-dilutive share awards totaling 300,000 were excluded from the computation of diluted EPS. We have 5,470,971 warrants outstanding (the "Warrants") as of September 30, 2022 to purchase common shares of Valaris Limited (the "Common Shares") which are exercisable for one Common Share per Warrant at an initial exercise price of $131.88 per Warrant, in each case as may be adjusted from time to time pursuant to the applicable warrant agreement. Upon issuance, the Warrants were exercisable for a period of seven years and will expire on April 29, 2028. The exercise of these Warrants into Common Shares would have a dilutive effect to the holdings of Valaris Limited's existing shareholders. These warrants are anti-dilutive for all periods presented for the Successor.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI https://asc.fasb.org/topic&trid=2144383 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration